In vivo acquisition of extended-spectrum beta-lactamase in Salmonella enteritidis during antimicrobial therapy.
The recovery of a Salmonella enteritidis strain that acquired resistance to beta-lactams (including cefotaxime), to aminoglycosides and to chloramphenicol subsequent to cefotaxime therapy is reported. This resistance pattern to beta-lactams was due to the presence of an extended-spectrum beta-lactamase. The isoelectric point of this extended-spectrum beta-lactamase was 6.3. The resistance genes were located on a transferable high-molecular-weight plasmid.
Barguellil
F
F
Laboratoire de Microbiologie, Hopital militaire de Tunis, Tunisia.
Burucoa
C
C
Amor
A
A
Fauchère
J L
JL
Fendri
C
C
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002439:Cefotaxime / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology; D002443:Ceftriaxone / Q000494:pharmacology; D018550:Cephalosporin Resistance / Q000235:genetics; D002511:Cephalosporins / Q000494:pharmacology; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008826:Microbial Sensitivity Tests; D012480:Salmonella Infections / Q000188:drug therapy*; D012477:Salmonella enteritidis / Q000187:drug effects* / Q000201:enzymology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002443:Ceftriaxone; D002442:Ceftazidime; D002439:Cefotaxime